Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61: 69–90.
   PubMed Web of Science ®Google Scholar
• André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16.
   PubMed Web of Science ®Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768–74.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352–8.
   PubMed Web of Science ®Google Scholar
• Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447–56.
   PubMed Web of Science ®Google Scholar
• Slevin ML, Papamichael D, Rougier P, Schmoll HJ. Is there a standard adjuvant treatment for colon cancer? Eur J Cancer 1998;34:1652–63.
   PubMed Web of Science ®Google Scholar
• Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;3:CD004078.
   Google Scholar
• Berardi R, Morgese F, Onofri A, Mazzanti P, Pistelli M, Ballatore Z, et al. Role of maspin in cancer. Clin Transl Med 2013;2:8.
   PubMedGoogle Scholar
• Zou Z, Anisowicz A, Hendrix MJ, Thor A, Neveu M, Sheng S, et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994; 263:526–9.
   PubMed Web of Science ®Google Scholar
• Zou Z, Zhang W, Young D, Gleave MG, Rennie P, Connel T, et al. Maspin expression profile in human prostate cancer (CaP) and in vitro induction of maspin expression by androgen ablation. Clin Cancer Res 2002;8:1172–7.
   PubMed Web of Science ®Google Scholar
• Solomon LA, Munkarah AR, Schimp VL, Arabi MH, Morris RT, Nassar H, et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol Oncol 2006;101:385–9.
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A, et al. Expression of maspin in non-muscle invasive bladder carcinoma: Correlation with tumor angiogenesis and prognosis. Eur Urol 2004;45:737–43.
   PubMed Web of Science ®Google Scholar
• Woenckhaus M, Bubendorf L, Dalquen P, Foerster J, Blaszyk H, Mirlacher M, et al. Nuclear and cytoplasmic maspin expression in primary non-small cell lung cancer. J Clin Pathol 2007;60:483–6.
   PubMed Web of Science ®Google Scholar
• Yoshizawa K, Nozaki S, Okamune A, Kitahara H, Ohara T, Kato K, et al. Loss of maspin is a negative prognostic factor for invasion and metastasis in oral squamous cell carcinoma. J Oral Pathol Med 2009;38:535–9.
   PubMed Web of Science ®Google Scholar
• Wang MC, Yang YM, Li XH, Dong F, Li Y. Maspin expression and its clinicopathological significance in tumorigenesis and progression of gastric cancer. World J Gastroenterol 2004;10:634–7.
   PubMed Web of Science ®Google Scholar
• Dietmaier W, Bettstetter M, Wild PJ, Woenckhaus M, Rümmele P, Hartmann A, et al. Nuclear maspin expression is associated with response to adjuvant 5-fluorouracil based chemotherapy in patients with stage III colon cancer. Int J Cancer 2006;118:2247–54.
   PubMed Web of Science ®Google Scholar
• Bodenstine TM, Seftor RE, Khalkhali-Ellis Z, Seftor EA, Pemberton PA, Hendrix MJ. Maspin: Molecular mechanisms and therapeutic implications. Cancer Metastasis Rev 2012;31:529–51.
   PubMed Web of Science ®Google Scholar
• Goulet B, Chan G, Chambers AF, Lewis JD. An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis. Biochem Cell Biol 2012;90:22–38.
   PubMed Web of Science ®Google Scholar
• Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, et al. Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol 2005;205:606–14.
   PubMed Web of Science ®Google Scholar
• Märkl B, Arnholdt HM, Jähnig H, Schenkirsch G, Herrmann RA, Haude K, et al. Shift from cytoplasmic to nuclear maspin expression correlates with shorter overall survival in node-negative colorectal cancer. Hum Pathol 2010;41:1024–33.
   PubMed Web of Science ®Google Scholar
• Umekita Y, Souda M, Yoshida H. Expression of maspin in colorectal cancer. In Vivo 2006;20:797–800.
   PubMed Web of Science ®Google Scholar
• Baek JY, Yeo HY, Chang HJ, Kim KH, Kim SY, Park JW, et al. Serpin B5 is a CEA-interacting biomarker for colorectal cancer. Int J Cancer 2014;134:1595–604.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180–4.
   PubMed Web of Science ®Google Scholar
• Dahl O, Fluge Ø, Carlsen E, Wiig JN, Myrvold HE, Vonen B, et al. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Acta Oncol 2009;48:368–76.
   PubMed Web of Science ®Google Scholar
• Barratt PL, Seymour MT, Stenning SP, Georgiades I, Walker C, Birbeck K, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: A molecular study. Lancet 2002;360:1381–91.
   PubMed Web of Science ®Google Scholar
• Fluge Ø, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 2009;101:1282–9.
   PubMed Web of Science ®Google Scholar
• Therneau TM, Grambsch PM. Modelling survival data. Extending the Cox model. New York (NY): Springer; 2000.
   Google Scholar
• Fung CL, Chan C, Jankova L, Dent OF, Robertson G, Molloy M, et al. Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer. Histopathology 2010;56:319–30.
   PubMed Web of Science ®Google Scholar
• Snoeren N, Emmink BL, Koerkamp MJ, van Hooff SR, Goos JA, van Houdt WJ, et al. Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer. Br J Cancer 2013;109:1636–47.
   PubMed Web of Science ®Google Scholar
• Song SY, Lee SK, Kim DH, Son HJ, Kim HJ, Lim YJ, et al. Expression of maspin in colon cancers: Its relationship with p53 expression and microvessel density. Dig Dis Sci 2002;47:1831–5.
   PubMed Web of Science ®Google Scholar
• Boltze C. Loss of maspin is a helpful prognosticator in colorectal cancer: A tissue microarray analysis. Pathol Res Pract 2005;200:783–90.
   PubMed Web of Science ®Google Scholar
• Zheng H, Tsuneyama K, Cheng C, Takahashi H, Cui Z, Murai Y, et al. Maspin expression was involved in colorectal adenoma-adenocarcinoma sequence and liver metastasis of tumors. Anticancer Res 2007;27:259–65.
   PubMed Web of Science ®Google Scholar
• Payne CM, Holubec H, Crowley-Skillicorn C, Nguyen H, Bernstein H, Wilcox G, et al. Maspin is a deoxycholate- inducible, anti-apoptotic stress-response protein differentially expressed during colon carcinogenesis. Clin Exp Gastroenterol 2011;4:239–53.
   PubMedGoogle Scholar
• Jang HL, Nam E, Lee KH, Yeom S, Son HJ, Park C. Maspin polymorphism associated with apoptosis susceptibility and in vivo tumorigenesis. Int J Mol Med 2008;22:333–8.
   PubMed Web of Science ®Google Scholar
• Myklebust MP, Li Z, Tran TH, Rui H, Knudsen ES, Elsaleh H, et al. Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer. Br J Cancer 2012;107:1684–91.
   PubMed Web of Science ®Google Scholar